Antileukemic activity of genistein, a major isoflavone present in soy products

Noël J-M Raynal1, Louise Momparler, Michel Charbonneau

  • 1INRS-Institut Armand-Frappier, Université du Québec, Laval, Canada.

Insights

Soy isoflavones, like genistein, show potential in fighting leukemia by reactivating tumor suppressor genes. A soy-rich diet may offer therapeutic benefits due to genistein

Area of Science:

  • Biochemistry
  • Oncology
  • Nutritional Science

Background:

  • Soy and its isoflavones have historical use in traditional medicine for various diseases, including cancer.
  • While animal models suggest cancer-preventing activity of soy isoflavones, their direct therapeutic effects against cancer remain under investigation.

Purpose of the Study:

  • To evaluate the in vitro and in vivo antileukemic activity of genistein, a primary soy isoflavone.
  • To investigate the mechanism of genistein's action, specifically its effect on tumor suppressor gene methylation in leukemic cells.

Main Methods:

  • In vitro assessment of genistein's antineoplastic effects on myeloid and lymphoid leukemic cell lines.
  • In vivo study using a genistein-enriched diet in mice to assess antileukemic effects.
  • Analysis of DNA methylation patterns and tumor suppressor gene reactivation following genistein treatment.

Main Results:

  • Genistein demonstrated dose- and time-dependent antineoplastic activity against leukemic cell lines in vitro.
  • Genistein treatment reactivated silenced tumor suppressor genes by reversing aberrant DNA methylation.
  • A genistein-enriched diet induced a moderate but significant antileukemic effect in mice.

Conclusions:

  • Genistein exhibits significant antileukemic properties, acting through the reactivation of tumor suppressor genes.
  • The rapid metabolic inactivation of genistein in mice may limit its in vivo efficacy.
  • Given its longer half-life in humans, a soy-enriched diet could achieve therapeutic genistein plasma levels for potential antileukemic activity.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...